Sohei Yoshimura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4670233/publications.pdf

Version: 2024-02-01

759233 552781 36 764 12 26 citations h-index g-index papers 36 36 36 1253 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cerebral microbleeds development after stroke thrombolysis: A secondary analysis of the THAWS randomized clinical trial. International Journal of Stroke, 2022, 17, 628-636.	5.9	10
2	Intensive blood pressure lowering with nicardipine and outcomes after intracerebral hemorrhage: An individual participant data systematic review. International Journal of Stroke, 2022, 17, 494-505.	5.9	5
3	Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. Annals of Neurology, 2022, 91, 78-88.	5.3	8
4	Practical "1-2-3-4-Day―Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke, 2022, 53, 1540-1549.	2.0	26
5	Intravenous Alteplase at 0.6 mg/kg for Unknown Onset Stroke with Prior Antithrombotic Medication: THAWS Randomized Clinical Trial. Journal of Atherosclerosis and Thrombosis, 2022, , .	2.0	O
6	Increased Cerebral Small Vessel Disease Burden With Renal Dysfunction and Albuminuria in Patients Taking Antithrombotic Agents: The Bleeding With Antithrombotic Therapy 2. Journal of the American Heart Association, 2022, 11, e024749.	3.7	5
7	Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage. Neurology, 2021, 96, e740-e751.	1.1	5
8	Intensive versus guidelineâ€recommended blood pressure reduction in acute lacunar stroke with intravenous thrombolysis therapy: The ENCHANTED trial. European Journal of Neurology, 2021, 28, 783-793.	3.3	8
9	Magnetic Resonance Imaging–Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size. Stroke, 2021, 52, 12-19.	2.0	9
10	Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke. Neurology, 2021, 96, e1512-e1526.	1.1	16
11	Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target. International Journal of Stroke, 2021, , 174749302110254.	5.9	O
12	Oral Anticoagulants in Atrial Fibrillation Patients With Recent Stroke Who Are Dependent on the Daily Help of Others. Stroke, 2021, 52, 3472-3481.	2.0	7
13	Impact of Renal Impairment on Intensive Blood-Pressure–Lowering Therapy and Outcomes in Intracerebral Hemorrhage. Neurology, 2021, 97, e913-e921.	1.1	13
14	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers, 2021, 13, 5282.	3.7	11
15	Transesophageal Echocardiography in Ischemic Stroke With Atrial Fibrillation. Journal of the American Heart Association, 2021, 10, e022242.	3.7	5
16	The bleeding with antithrombotic therapy study 2: Rationale, design, and baseline characteristics of the participants. European Stroke Journal, 2020, 5, 423-431.	5.5	3
17	A nomogram to predict unfavourable outcome in patients receiving oral anticoagulants for atrial fibrillation after stroke. European Stroke Journal, 2020, 5, 384-393.	5.5	5
18	Left Atrial Size and Ischemic Events after Ischemic Stroke or Transient Ischemic Attack in Patients with Nonvalvular Atrial Fibrillation. Cerebrovascular Diseases, 2020, 49, 619-624.	1.7	8

#	Article	IF	CITATIONS
19	Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm. Cerebrovascular Diseases, 2020, 49, 427-436.	1.7	2
20	Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Lancet, The, 2020, 396, 1574-1584.	13.7	107
21	Thrombolysis Outcomes in Acute Ischemic Stroke by Fluid-Attenuated Inversion Recovery Hyperintense Arteries. Stroke, 2020, 51, 2240-2243.	2.0	7
22	Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset. Stroke, 2020, 51, 1530-1538.	2.0	55
23	Sex Differences in Blood Pressure–Lowering Therapy and Outcomes Following Intracerebral Hemorrhage. Stroke, 2020, 51, 2282-2286.	2.0	10
24	Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. Annals of Neurology, 2020, 87, 677-687.	5.3	117
25	Early Initiation of Direct Oral Anticoagulants After Onset of Stroke and Short- and Long-Term Outcomes of Patients With Nonvalvular Atrial Fibrillation. Stroke, 2020, 51, 883-891.	2.0	31
26	Concentrations of dabigatran administered after acute ischemic stroke. Journal of the Neurological Sciences, 2020, 411, 116704.	0.6	3
27	Clinical prognosis of FLAIR hyperintense arteries in ischaemic stroke patients: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 475-482.	1.9	9
28	Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Annals of Neurology, 2019, 85, 823-834.	5.3	84
29	Associations of High Intensities on Magnetization-Prepared Rapid Acquisition with Gradient Echo with Aortic Complicated Lesions in Ischemic Stroke Patients. Cerebrovascular Diseases, 2019, 47, 15-23.	1.7	5
30	NIHSS cut point for predicting outcome in supra- vs infratentorial acute ischemic stroke. Neurology, 2018, 91, e1695-e1701.	1.1	13
31	Early Achievement of Blood Pressure Lowering and Hematoma Growth in Acute Intracerebral Hemorrhage: Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study. Cerebrovascular Diseases, 2018, 46, 116-122.	1.7	8
32	Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation ― SAMURAI-NVAF Study ―. Circulation Journal, 2018, 82, 1935-1942.	1.6	35
33	Prothrombin complex concentrate administration for bleeding associated with non-vitamin K antagonist oral anticoagulants: The SAMURAI-NVAF study. Journal of the Neurological Sciences, 2017, 375, 150-157.	0.6	12
34	Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation. Stroke, 2016, 47, 2582-2588.	2.0	43
35	Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. International Journal of Stroke, 2016, 11, 565-574.	5.9	75
36	Cerebral Small-Vessel Disease in Neuro-Behçet Disease. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, e237-e239.	1.6	4